Processing

Please wait...

Settings

Settings

Goto Application

1. WO2022002153 - DRUG FOR TREATING TUMOR

Publication Number WO/2022/002153
Publication Date 06.01.2022
International Application No. PCT/CN2021/103687
International Filing Date 30.06.2021
IPC
C07K 16/28 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
C12N 15/13 2006.1
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
12Genes encoding animal proteins
13Immunoglobulins
A61K 39/395 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
A61P 37/02 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
37Drugs for immunological or allergic disorders
02Immunomodulators
Applicants
  • 正大天晴药业集团股份有限公司 CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. [CN]/[CN]
Inventors
  • 苏楠 SU, Nan
  • 张喜全 ZHANG, Xiquan
  • 陈杰 CHEN, Jie
  • 王训强 WANG, Xunqiang
  • 李琨 LI, Kun
  • 于鼎 YU, Ding
  • 汪荣亮 WANG, Rongliang
Agents
  • 北京信慧永光知识产权代理有限责任公司 BEIJING SUNHOPE INTELLECTUAL PROPERTY LTD.
Priority Data
202010619083.830.06.2020CN
202010619111.630.06.2020CN
202010620778.830.06.2020CN
Publication Language Chinese (zh)
Filing Language Chinese (ZH)
Designated States
Title
(EN) DRUG FOR TREATING TUMOR
(FR) MÉDICAMENT POUR LE TRAITEMENT DE TUMEUR
(ZH) 用于治疗肿瘤的药物
Abstract
(EN) The present invention belongs to the field of biomedicines, relates to a drug for treating tumors, and provides use of an anti-PD-L1 antibody or a pharmaceutical composition thereof in preparation of a drug for treating endometrial cancer. Also provided is use of the anti-PD-L1 antibody or the pharmaceutical composition thereof in preparation of a drug for treating a MSI-H and/or dMMR tumor. In addition, also provided is use of a pharmaceutical combination of the anti-PD-L1 antibody and Anlotinib or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof in preparation of a drug for treating endometrial cancer.
(FR) La présente invention relève du domaine des biomédicaments, et concerne un médicament pour le traitement de tumeurs, ainsi que l'utilisation d'un anticorps anti-PD-L1 ou d'une composition pharmaceutique de celui-ci dans la préparation d'un médicament pour le traitement du cancer de l'endomètre. L'invention concerne également l'utilisation de l'anticorps anti-PD-L1 ou de la composition pharmaceutique de celui-ci dans la préparation d'un médicament pour le traitement d'une tumeur MSI-H et/ou dMMR. De plus, l'invention concerne également l'utilisation d'une combinaison pharmaceutique de l'anticorps anti-PD-L1 et de l'anlotinib ou d'un sel pharmaceutiquement acceptable de celui-ci, ou d'une composition pharmaceutique de celui-ci dans la préparation d'un médicament pour le traitement du cancer de l'endomètre.
(ZH) 属于生物医药领域,涉及用于治疗肿瘤的药物,提供了抗PD-L1抗体或其药物组合物在制备用于治疗子宫内膜癌的药物中的用途。还提供了抗PD-L1抗体或其药物组合物在制备用于治疗MSI-H和/或dMMR肿瘤的药物中的用途。另外,还提供了抗PD-L1抗体和安罗替尼或其药学上可接受的盐的药物组合或药物组合物在制备用于治疗子宫内膜癌的药物中的用途。
Latest bibliographic data on file with the International Bureau